Singapore grants interim authorisation for Pfizer bivalent COVID-19 booster vaccine

Singapore grants interim authorisation for Pfizer bivalent COVID-19 booster vaccine

The Health Sciences Authority (HSA) on Tuesday (Oct 25) granted interim authorisation for Pfizer's Comirnaty bivalent COVID-19 booster vaccine in Singapore.

There are many novice players สล็อตxo who are still worried about the investment and the sheer amount of money that makes it impossible to invest. SLOTXO CAMP 

This makes it the second such jab to be approved for use here after the Moderna/Spikevax vaccine, which obtained interim authorisation in September and was rolled out earlier in October.

The Comirnaty Bivalent (Original/Omicron BA.4/5) COVID-19 jab by Pfizer is an updated version of the original Comirnaty vaccine.

It comprises two components - 15 micrograms targeting the original SARS-CoV-2 strain and 15 micrograms targeting the Omnicron BA.4 and BA.5 variants, said HSA in a news release.

The Comirnaty bivalent vaccine is authorised for use as a booster shot for individuals aged 12 and above, who have received primary series COVID-19 vaccination.

Health Minister Ong Ye Kung has said that bivalent vaccines provide better protection against newer COVID-19 variants compared to the original vaccines.

Last week, he announced that Singapore plans to invite people aged between 18 and 49 to take their COVID-19 bivalent vaccines later in the year, as more supplies are secured.